Assessment of Protein Prenylation Pathway in Multiple Sclerosis Patients
Multiple sclerosis (MS) is a chronic inflammatory disorder with several genetic and environmental factors being implicated in its pathogenesis. Protein prenylation as one of the important posttranslational modifications of proteins has crucial role in immune system regulation. In the current case–control study, we compared expression of five genes coding for the different subunits of proteins implicated in protein prenylation in 50 Iranian MS patients with those of healthy subjects. No significant difference has been found in FNTA and PGGT1B expressions between cases and controls. Spearman correlation analysis between FNTA relative expression and disease duration showed significant correlation in male patients (r = − 0.671, P = 0.024) but not female patients (r = 0.253, P = 0.12). FNTB expression was significantly higher in MS patients compared with healthy subjects. Spearman correlation analysis between FNTB relative expression and disease duration showed significant correlation in male patients (r = −0.876, P = 0.004) but not female patients (r = 0.296, P = 0.06). RABGGTA was significantly upregulated in total MS patients, total male patients, female patients aged between 30 and 40 and male patients aged >40 compared with corresponding control groups. RABGGTB was significantly downregulated in total MS patients, total female patients, and female patients aged > 40 compared with corresponding control groups. Totally, we demonstrated dysregulation of protein prenylation pathway in MS patients compared with healthy subjects. Future studies are needed to find the clinical implication of this pathway in MS patients.
KeywordsMultiple sclerosis FNTA FNTB PGTT1B RABGGTA RABGGTB Prenylation
The current study was supported by a grant number 10250 from the Shahid Beheshti University of Medical Sciences.
Compliance with Ethical Standards
This study was compliance with ethical committe of Shahid Beheshti University of MedicalSciences (IR.SBMU. MSP.REC.1396.44).
- Greenwood J, Steinman L, Zamvil SS (2006) Statin therapy in autoimmunity: from protein prenylation to immunomodulation. Nat RevImmuno l6Google Scholar
- Magyari M (2016) Gender differences in multiple sclerosis epidemiology and treatment response. Dan Med J 63Google Scholar
- Mazdeh M, Noroozi R, Gharesouran J, Sayad A, Komaki A, Eftekharian MM, Habibi M, Toghi M, Taheri M (2017) The importance of VEGF-KDR signaling pathway genes should not be ignored when the risk of developing multiple sclerosis is taken into consideration. J Mol Neurosci 62:73–78CrossRefPubMedGoogle Scholar
- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302CrossRefPubMedPubMedCentralGoogle Scholar
- Trentini A, Manfrinato MC, Castellazzi M, Tamborino C, Roversi G, Volta CA, Baldi E, Tola MR, Granieri E, Dallocchio F, Bellini T, Fainardi E (2015) TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis. Mult Scler 21:1121–1130CrossRefPubMedGoogle Scholar